Buxton, M., Alexander, B., Berry, D., Cavenee, W., Colman, H., de Groot, J., … Cloughesy, T. (2022). UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. In NEURO-ONCOLOGY (Vol. 24, pp. 80–80).

Buxton, Meredith, Brian Alexander, Donald Berry, Webster Cavenee, Howard Colman, John de Groot, Benjamin Ellingson, et al. “UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.” In NEURO-ONCOLOGY, 24:80–80, 2022.

Buxton M, Alexander B, Berry D, Cavenee W, Colman H, de Groot J, et al. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2022. p. 80–80.

Buxton, Meredith, et al. “UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.” NEURO-ONCOLOGY, vol. 24, 2022, pp. 80–80.

Buxton M, Alexander B, Berry D, Cavenee W, Colman H, de Groot J, Ellingson B, Gordon G, Khasraw M, Lassman A, Lee E, Li W, Lim M, Mellinghoff I, Mikkelsen T, Nelli A, Perry J, Sulman E, Tanner K, Weller M, Wen PY, Yung WKA, Cloughesy T. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. NEURO-ONCOLOGY. 2022. p. 80–80.